The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
If Melafinds phase three study results are positive then physicians will in general be receptive. The only issues are: 1. Ease of use/time to scan 2. Ability for non physician personnel to be trained to use the technology. 3. cost 4. Insurance reimbursement The technology may have more use at larger...
The new Modus product "without hydroquinone" cannot be fully evaluated on the basis of the currently available information. Decisions based on the opinions of a "Beauty Editor", and 6 years worth of studies with only 4 patients, are tenuous at best, and laughable at worst. It will be difficult to unseat...
Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis
Discount cosmetic surgery is already here, but not via large commercial companies. Retention of actual plastic and reconstructive surgeons may be difficult if they are not paying well. There is a place for this, however the solo practitioner will continue to have word of mouth and a place....
I have yet to see any study that would prclude me from recommending these products. I believe if utilized correctly and dosed appropriately it would be a disservice to our patients if the ability to prescribe this were taken away.
The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...
Stock was up on preliminary FDA approval, however, the FDA has mandated that final approval would be dependent on ongoing trial. This will certainly delay any growth for Dendreon/Provenge at this time.
The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove...